

BIBLIOGRAFIA

- 1) Alonso K., Pontiggia P., Sabato A. et al: Systemic hyperthermia in the treatment of HIV related disseminated Kaposi's Sarcoma. Long term follow-up of patients treated with low flow extracorporeal perfusional hyperthermia. *Am. J. Clin. Oncol.* , 17: 353, 1994
- 2) Di Filippo F., Carlini S., Cavaliere F., Giannarelli D., Cavallero L. et al: The role of hyperthermic perfusion in the treatment of tumors of the extremities. In: "Consensus on hyperthermia for the 1990's". *Adv. Exp. Med. And Biol.* Vol 267, Plenum Press 1990
- 3) Leveen H., Wapnick G., Piccone V.A., Falk G. and Ahmed N.: Tumor eradication by radiofrequency thermotherapy. *Jama* , 235, 2198, 1976
- 4) Streffer C.: Metabolic changes during and after hyperthermia. *Int. Journal of hyperthermia* , 1: 305, 1985
- 5) Pontiggia P., McLaren J., Baronzio G., Freitas I.: The biological response to heat. In: "Consensus on hyperthermia for the 1990's", *Adv. Exp. Med. And Biol.* Vol. 267, Plenum Press, 1990.
- 6) Dahl O.: Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity in hyperthermia and oncology. *Urano and Douple Eds. VPS Utrecht, 1994*
- 7) Pontiggia P. Mathè G.: A new mode of cancer cell death induced by hyperthermia and non specific (macrophagic) cancer immunotherapy: lysosomal exocytosis. *Biomed. Pharmacother.*: 48, 331, 1994
- 8) Pontiggia P., Barni S. Mathè G., Bertone V. Pontiggia E.: Lysosomal exocytosis induced by hyperthermia: a new model of cancer death II- Effect on peritoneal macrophages. *Biomed. Pharmacother.* . 49, 1995
- 9) Los G., Van Vugt MJH, Pinedo HM: Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with Cisplatin or Carboplatin. *Br. J. Cancer* 1994; 69. 235-41
- 10) Rau B., Wust P., Hohenberger P., Loffel H.M., Below C. et al: Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer. *Annals of Surgery* 227, 3, 380-389; 1998
- 11) Reitbroek R., Schglthuis M, bakker P., Van Dijk J, Postma A. et al: Phase II trial of weekly locoregional hyperthermia and Cisplatin in patients with previously irradiated recurrent carcinoma of uterine cervix. *Cancer* 1997; 79: 935-43
- 12) Lucchetti F., Burattini S., Ferri P., Papa S., Falcieri E.: Actin involvement in apoptotic chromatin changes of hemopoietic cells undergoing hyperthermia. *Apoptosis* 2002 ; 7(2): 143-52
- 13) Wachsberger P., Burd R. Wahl M, Leeper D.B.: Betulinic acid sensitization of low pH adapted human melanoma cells to hyperthermia. *Int. J. Hyperthermia* 2002; 18 (2): 153-64

- 14) Hildebrandt B., Wust P., Ahlers O., Dieing A., Kerner T. et al: The cellular and molecular basis of hyperthermia. *Crit. Rev. Oncol. Hematol* 2002; 43 (1): 33-56
- 15) Yuguchi T., Saito M., Yokoyama Y, Nagata T. Sakamoto T. Tsukada K.: Combined use of hyperthermia and irradiation cause antiproliferative activity and cell death to human esophageal carcinoma cells: mainly cycle examination. *Hum. Cell* 2002; 15 (1) 33-42
- 16) Wust P. Hildebrandt B., Sreenivasa G., Rau B. Gellermann J. et al: Hyperthermia in combined treatment of cancer. *Lancet Oncol* 2002; 3 (8); 487-97
- 17) Li G.C., Mivechi N. and Weitzel G.: Heat shock proteins, thermotolerance and their relevance for clinical hyperthermia. *Int. J. Hyperthermia* 1995; 11, 459-488
- 18) Field SB, Franconi C, editors. *Physics and Technology of Hyperthermia* . Boston: Nijhoff, 1987
- 19) RA Read and JS Bedford. Thermal tolerance *Br J Radiol* 1980. 53: 920-921
- 20) Hahn GM, Adwankar MK, Basur VS, Anderson RL. Survival of cells exposed to anticancer drugs after stress. In: Pardue ML, Feramisco JR, Lindquist S. *Stress-Induced Proteins* . New York, NY: Liss; 1989. p. 223 233
- 21) Hiraoka and GM Hahn. Changes in pH and blood flow induced by glucose and their effects on hyperthermia with or without BCNU in RIF-1 tumours *Int J Hypertherm* 1990. 6: 97-103
- 22) Morimoto RI, Tissieres A, Georgopoulos C. *Stress Proteins in Biology and Medicine*. Cold Spring Harbor, New York. 1990.
- 23) HI Robins, A Hugander, and JD Cohen. Whole body hyperthermia in the treatment of neoplastic disease *Radiol Clin North Am* 1989. 27: 603-610.
- 24) TV Samulski, ST Clegg, S Das, J MacFall, and DM Prescott. Application of new technology in clinical hyperthermia *Int J Hypertherm* 1994. 10: 389-394.
- 25) JR Oleson, TV Samulski, KA Leopold, ST Clegg, MW Dewhirst, RK Dodge, and SL George. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment *Int J Radiat Oncol . Biol Phys* 1993. 25: 289-297.
- 26) DS Kapp and R Cox. Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast *Int J Radiat Oncol Biol Phys* 1995. 33: 887-899.
- 27) J van der Zee, GC van Rhoon, JL Wike-Hooley, NS Faithfull, and HS Reinhold. Whole-body hyperthermia in cancer therapy: a report of a phase I-II study *Eur J Cancer Clin Oncol* 1983. 19: 1189-1200.
- 28) M Serin, HS Erkal, and A Cakmak. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with recurrent carcinomas of the head and neck with metastatic cervical lymph nodes *Int J Hyperthermia* 1999. 15: 371-381.
- 29) CC Vernon. International Collaborative Hyperthermia Group. Radio therapy with or

without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials *Int J Radiol Oncol Biol Phys* 1996. 35: 731-744.

30) J Overgaard, D Gonzalez Gonzalez, MCCM Hulshof, G Arcangeli, O Dahl, O Molls, and SM Bentzen. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma *Lancet* 1995. 345: 540-543.

31) R Valdagni and M Amichetti. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph-nodes in Stage IV head and neck patients *Int J Radiat Oncol Biol Phys* 1994. 28: 163-169.

32) IA Petersen and DS Kapp. Local hyperthermia and radiation therapy in the retreatment of superficially located recurrences in Hodgkin's disease *Int J Radiat Oncol Biol Phys* 1990. 18: 603-611

33) T Sakamoto, H Katoh, T Shimizu, I Yamashita, S Takemori, K Tazawa, and M Fujimaki. Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy *Chest* 1997. 112: 1487-1493.

34) LH Hartwell and TA Weinert. Checkpoints: controls that ensure the order of cell cycle events *Science* 1989. 246: 629-634.

35) DO Morgan. Cyclin-dependent kinases: engines, clocks, and microprocessors *Ann Rev Cell Dev Biol* 1997. 13: 261-291.

36) G Zugmaier and ME Lippman. Effects of TGF beta on normal and malignant mammary epithelium *Ann N Y Acad Sci* 1990. 593: 272-275.

37) BJ Druker, HJ Mamon, and TM Roberts. Oncogenes, growth factors, and signal transduction *N Engl J Med* 1989. 321: 1383-1391.

38) AB Pardee. G1 events and regulation of cell proliferation *Science* 1989. 246: 603-608.

39) DW Goodrich, NP Wang, YW Qian, EY Lee, and WH Lee. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle *Cell* 1991. 67: 293-302.

40) S Barni, P Pontiggia, V Bertone, R Vaccarone, MG Siulvotti, E Pontiggia, G Mathè. Hyperthermia-induced cell death by apoptosis in myeloma cells. *Biomed Pharmacother* 2001; 55: 170-3

41) V Bertone, S Barni, MG Silvotti, I Freitas, G Mathè et al. Hyperthermic effect on the human metastatic liver: a TEM study. *Anticancer Res.* 1997; 17: 4713-6

42) A Amundson, TG Myers, AJ Fornace, and Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress *Oncogene* 1998. 17: 3287-3299

43) JI Fabrikant and J Cherry. The kinetics of cellular proliferation in normal and malignant tissues. V. Analysis of labeling indices and potential tissue doubling times in human tumor cell populations *J Surg Oncol* 1969. 1: 23-47.

44) K Fukuda, T Iwasaka, and T Hachisuga *et al* . Immunocytochemical detection of S-phase cells in normal and neoplastic cervical epithelium by anti-BrdU monoclonal antibody *Anal*

- Quant Cytol Histol* 1990. 12: 135-138.
- 45) L Teodori, ML Trinca, and W Goehde *et al* . Cytokinetic investigation of lung tumors using the anti-bromodeoxyuridine (BUdR) monoclonal antibody method: comparison with DNA flow cytometric data *Int J Cancer* 1990. 45: 995-1001.
- 46) G Weber. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture *Cancer Res* 1983. 43: 3466-3492.
- 47) R Juliano. Cooperation between soluble factors and integrin-mediated cell anchorage in the control of cell growth and differentiation *Bioessays* 1996. 18: 911-917.
- 48) M Hall and G Peters. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer *Adv Cancer Res* 1996. 68: 67-108.
- 49) CJ Sherr. Cancer cell cycles *Science* 1996. 274: 1672-1677.
- 50) A Kamb. Cyclin-dependent kinase inhibitors and human cancer *Curr Top Microbiol Immunol* 1998. 227: 139-148
- 51) DW Goodrich and WH Lee. The molecular genetics of retinoblastoma *Cancer Surveys* 1990. 9: 529-554
- 52) C Prives and PA Hall. The p53 pathway *J Pathol* 1999. 187: 112-126.
- 53) M Akashi and HP Koeffler. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility *Clin Obstet Gynecol* 1998. 41: 172-199
- 54) N Weidner, PR Carroll, J Flax, W Blumenfeld, and J Folkman. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma *Am J Pathol* 1993. 143: 401-409.
- 55) N Weidner, JP Semple, WR Welch, and J Folkman. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma *N Engl J Med* 1991. 324: 1-8.
- 56) LR Bernstein and LA Liotta. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis *Curr Opin Oncol* 1994. 6: 106-113.
- 57) B Mintz and RA Fleischman. Teratocarcinomas and other neoplasms as developmental defects in gene expression *Adv Cancer Res* 1981. 34: 211-278.
- 58) MF Pittenger, AM Mackay, and SC Beck *et al* . Multilineage potential of adult human mesenchymal stem cells *Science* 1999. 284: 143-147.
- 59) JJ Wille Jr , PB Maercklein, and RE Scott. Neoplastic transformation and defective control of cell proliferation and differentiation *Cancer Res* 1982. 42: 5139-5146.
- 60) DB Rifkin and D Moscatelli. Recent developments in the cell biology of basic fibroblast growth factor *J Cell Biol* 1989. 109: 1-6.
- 61) E Rozengurt. Early signals in the mitogenic response *Science* 1986. 234: 161-166
- 62) HL Moses, EY Yang, and JA Pietsenpol. TGF-beta stimulation and inhibition of cell

- proliferation: new mechanistic insights *Cell* 1990. 63: 245-247.
- 63) M Peter and I Herskowitz. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle [comment] *Cell* 1994. 79: 181-184.
- 64) CJ Sherr. G1 phase progression: cycling on cue [see comments] *Cell* 1994. 79: 551-555.
- 65) JL Bennington. Cellular kinetics of invasive squamous carcinoma of the human cervix *Cancer Res* 1969. 29: 1082-1088.
- 66) V Castronovo, M Kusaka, A Chariot, J Gielen, and M Sobel. Homeobox genes: potential candidates for the transcriptional control of the transformed and invasive phenotype *Biochem Pharmacol* 1994. 47: 137-143
- 67) A McCormick and J Campisi. Cellular aging and senescence *Curr Opin Cell Biol* 1991. 3: 230-234.
- 68) R Singal and GD Ginder. DNA methylation *Blood* 1999. 93: 4059-4070.
- 69) AP Feinberg and B Vogelstein. Hypomethylation distinguishes genes of some human cancers from their normal counterparts *Nature* 1983. 301: 89-92.
- 70) SE Goelz, B Vogelstein, SR Hamilton, and AP Feinberg. Hypomethylation of DNA from benign and malignant human colon neoplasms *Science* 1985. 228: 187-190.
- 71) M Carlsson, TH Totterman, P Matsson, and K Nilsson. Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA *Blood* 1988. 71: 415-421
- 72) Gorstein F, Thor A. Tumor markers in diagnostic pathology. In *Clinics in Laboratory Medicine*. Edited by F Gorstein, A Thor. Philadelphia: WB Saunders, 1990.
- 73) M Reiss, C Gamba-Vitalo, and AC Sartorelli. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms *Cancer Treat Rep* 1986. 70: 201-218
- 74) Waxman S, Rossi GB, Takaku F. *The Status of Differentiation Therapy of Cancer*. New York: Raven, 1988.
- 75) M Andreeff, R Stone, and J Michaeli *et al* . Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A Phase II clinical trial with a differentiation-inducing agent *Blood* 1992. 80: 2604-2609.
- 76) TR Breitman, SJ Collins, and BR Keene. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid *Blood* 1981. 57: 1000-1004.
- 77) BA Chabner. Biological basis for cancer treatment [comment] *Ann Intern Med* 1993. 118: 633-637.
- 78) BD Cheson, DM Jasperse, HG Chun, and MA Friedman. Differentiating agents in the treatment of human malignancies *Cancer Treat Rev* 1986. 13: 129-145.

- 79) M Andreeff, S Jiang, and X Zhang *et al* . Expression of bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retionic acid *Leukemia* 1999. 13: 1881-1892.
- 80) WK Hong, SM Lippman, and LM Itri *et al* . Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck [see comments] *N Engl J Med* 1990. 323: 795-801.
- 81) FL Meyskens Jr . Coming of age the chemoprevention of cancer [editorial; comment] [see comments] *N Engl J Med* 1990. 323: 825-827.
- 82) JD Rowley, JC Aster, and J Sklar. The clinical applications of new DNA diagnostic technology on the management of cancer patients *JAMA* 1993. 270: 2331-2337.
- 83) JC Reed. Dysregulation of apoptosis in cancer *J Clin Oncol* 1999. 17: 2941-2953.
- 84) MO Hengartner and HR Horvitz. Programmed cell death in *Caenorhabditis elegans* *Curr Opin Genet Dev* 1994. 4: 581-586.
- 85) K Hofmann, P Bucher, and J Tschopp. The CARD domain: a new apoptotic signalling motif *Trends Biochem Sci* 1997. 22: 155-156.
- 86) P Li, D Nijhawan, and I Budihardjo *et al* . Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade *Cell* 1997. 91: 479-489
- 87) JJ Chou, H Matsuo, H Duan, and G Wagner. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment *Cell* 1998. 94: 171-180.
- 88) K Kuida, TF Haydar, and CY Kuan *et al* . Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking Caspase 9 *Cell* 1998. 94: 325-337.
- 89) DW Nicholson and NA Thornberry. Caspases: killer proteases *Trends Biochem Sci* 1997. 22: 299-306.
- 90) RV Talanian, C Quinlan, and S Trautz *et al* . Substrate specificities of caspase family proteases *J Biol Chem* 1997. 272: 9677-9682.
- 91) NA Thornberry, TA Rano, and EP Peterson *et al* . A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis *J Biol Chem* 1997. 272: 17907-17911.
- 92) MP Boldin, TM Goncharov, YV Goltsev, and D Wallach. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death *Cell* 1996. 85: 803-815.
- 93) M Muzio, AM Chinnaiyan, and FC Kischkel *et al* . FLICE, a novel FADD1-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex *Cell* 1996. 85: 817-827.
- 94) L Faleiro, R Kobayashi, H Fearnhead, and Y Lazebnik. Multiple species of CPP32 and

- Mch2 are the major active caspases present in apoptotic cells *EMBO J* 1997. 16: 2271-2281.
- 95) M MacFarlane, K Cain, XM Sun, ES Alnemri, and GM Cohen. Processing/activation of at least four interleukin-1 beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells *J Cell Biol* 1997. 37: 469-479.
- 96) SM Srinivasula, T Fernandes-Alnemri, and J Zangrilli *et al* . The CED-3/interleukin-1 beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for the apoptotic mediator CPP32 *J Biol Chem* 1996. 271: 27099-27106.
- 97) X Liu, CN Kim, J Yang, R Jemmerson, and X Wang. Induction of apoptotic programin cell-free extracts: requirement for dATP and cytochrome c *Cell* 1996. 86: 147-157.
- 98) J Yang, X Liu, and K Bhalla *et al* . Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked [see comments] *Science* 1997. 275: 1129-1132.
- 99) DR Green and JC Reed. Mitochondria and apoptosis *Science* 1998. 281: 1309-1312.
- 100) DR Green. Apoptotic pathways: the roads to ruin *Cell* 1998. 94: 695-698.
- 101) H Sakahira, M Enari, and S Nagata. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis [see comments] *Nature* 1998. 391: 96-99.
- 102) N Fujita, A Nagahashi, K Nagashima, S Rokudai, and T Tsuruo. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases *Oncogene* 1998. 17: 1295-1304.
- 103) EH Cheng, DG Kirsch, and RJ Clem *et al* . Conversion of bcl-2 to a Bax-like death effector by caspases *Science* 1997. 278: 1966-1968.
- 104) RA MacCorkle, KW Freeman, and DM Spencer. Synthetic activation of caspases: artificial death switches *Proc Natl Acad Sci U S A* 1998. 95: 3655-3660.
- 105) RJ Clem and LK Miller. Control of programmed cell death by the baculovirus genes p35 and iap *Mol Cell Biol* 1994. 14: 5212-5222.
- 106) N Roy, MS Mahadevan, and M McLean *et al* . The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy *Cell* 1995. 80: 167-178.
- 107) AG Uren, M Pakusch, CJ Hawkins, KL Puls, and DL Vaux. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors *PNAS* 1996. 93: 4974-4978.
- 108) HR Stennicke, QL Deveraux, and EW Humke *et al* . Caspase-9 can be activated without proteolytic processing *J Biol Chem* 1999. 274: 8359-8362.
- 109) QL Deveraux, N Roy, and HR Stennicke *et al* . IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases *EMBO J* 1998. 17: 2215-2223
- 110) J Dierlamm, M Baens, and I Wlodarska *et al* . The apoptosis inhibitor gene API2 and a

novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6 associated with mucosa-associated lymphoid tissue lymphomas *Blood* 1999. 93: 3601-3609.

111) A Greiner, H Seeberger, C Knorr, P Starostik, and HK Muller-Hermelinck. MALT-type B-cell lymphomas escape the sensing FAS-mediated apoptosis *Blood* 1998. 92: 484a.

112) G Ambrosini, C Adida, and DC Altieri. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma *Nat Med* 1997. 3: 917-921.

113) F Li, G Ambrosini, and EY Chu *et al* . Control of apoptosis and mitotic spindle checkpoint by survivin *Nature* 1998. 396: 580-584.

114) I Tamm, Y Wang, E Sausville, DA Scudiero, N Vigna, T Oltersdorf, and JC Reed. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs *Cancer Res* 1998. 58: 5315-5320.

115) CD Lu, DC Altieri, and N Tanigawa. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas *Cancer Res* 1998. 58: 1808-1812.

116) H Kawasaki, DC Altieri, and CD Lu *et al* . Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer *Cancer Res* 1998. 58: 5071-5074.

117) G Ambrosini, C Adida, G Sirugo, and DC Altieri. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting *J Biol Chem* 1998. 273: 11177-11182.

118) C Adida, PL Crotty, and J McGrath *et al* . Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation *Am J Pathol* 1998. 152: 43-49.

119) CA Smith, T Farrah, and RG Goodwin. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death *Cell* 1994. 76: 959-962.

120) S Nagata. Apoptosis by death factor *Cell* 1997. 88: 355-365.

121) M Hahne, D Rimoldi, and M Schroter *et al* . Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape *Science* 1996. 274: 1363-1366.

122) S Nagata and P Golstein. The Fas death factor *Science* 1997. 267: 1449-1456.

123) AM Chinnaiyan, K O'Rourke, M Tewari, and VM Dixit. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis *Cell* 1995. 81: 505-512.

124) AM Chinnaiyan, CG Tepper, and MF Seldin *et al* . FADD/MORT1 is a common mediator of CD95 (Fas/APO1) and tumor necrosis factor receptor-induced apoptosis *J Biol Chem* 1996. 271: 4961-4965.

125) M Muller, S Wilder, and D Bannasch *et al* . p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs *J Exp Med* 1998. 188: 2033-2045.

126) LB Owen-Schaub, W Zhang, and JC Cusack *et al* . Wild-type human p53 and a

temperature-sensitive mutant induce Fas/APO-1 expression *Mol Cell Biol* 1995. 15: 3032-3040.

127) J Ogasawara, R Watanabe-Fukunaga, and M Adachi *et al* . Lethal effect of the anti-fas antibody in mice *Nature* 1993. 364: 806-809.

128) P Schneider, N Holler, and JL Bodmer *et al* . Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity *J Exp Med* 1998. 187: 1205-1213.

129) J Kitson, T Raven, and YP Jiang *et al* . A death-domain-containing receptor that mediates apoptosis *Nature* 1996. 384: 372-375.

130) AM Chinnaiyan, K O'Rourke, and GL Yu *et al* . Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95 *Science* 1996. 274: 990-992.

131) Y Hitoshi, J Lorens, and SI Kitada *et al* . Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells *Immunity* 1998. 8: 461-471.

132) RW Johnstone, E Cretney, and MJ Smyth. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death *Blood* 1999. 93: 1075-1085.

133) WD Thomas and P Hersey. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells *J Immunol* 1998. 161: 2195-2200.

134) V Snell, K Clodi, and S Zhao *et al* . Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies *Br J Cancer* 1997. 99: 624.

135) M Andreeff, G Wong, B Koziner, E Espiritu, and B Clarkson. Non B-Non T acute lymphoblastic leukemia (ALL): evidence for complete b cell differentiation of a quiescent subpopulation and their response to induction therapy *Proc Am Assoc Cancer Res* 1985. 26: 28.

136) MM Keane, SA Ettenberg, MM Nau, EK Russell, and S Lipkowitz. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines *Cancer Res* 1999. 59: 734-741.

137) P Golstein. Cell death: trail and its receptors *Curr Biol* 1997. 7: R750-R753.

138) H Walczak, RE Miller, and K Ariail *et al* . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo [see comments] *Nat Med* 1999. 5: 157-163.

139) L Gibson, SP Holmgren, and DC Huang *et al* . Bcl-w, a novel member of the bcl-2 family, promotes cell survival *Oncogene* 1996. 13: 665-675.

140) E Yang, J Zha, and J Jockel *et al* . Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death *Cell* 1995. 80: 285-291.

141) M JJ Hunter, BL Bond, and TG Parslow. Functional dissection of the human Bcl2 protein: sequence requirements for inhibition of apoptosis *Mol Cell Biol* 1996. 16: 877-883.

142) C Borner, I Martinou, and C Mattmann *et al* . The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis *J Cell Biol* 1994. 126: 1059-1068.

143) T Ito, X Deng, B Carr, and WS May. Bcl-2 phosphorylation required for anti-apoptosis function *J Biol Chem* 1997. 272: 11671-11673.

144) MV Blagosklonny, T Schulte, P Nguyen, J Trepel, and LM Neckers. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway *Cancer Res* 1996. 56: 1851-1854.